your market intelligence analyst
Search Results
93 results
Your search is now limited to «Biogen» expert search.
ENDPOINTS 08/20/2019 10:15
→ Most of Big Pharma has left the building when it comes to antimicrobial drug development, and small companies with newly approved antibiotics are struggling to stay afloat. Meanwhile, the foundation arm of Pfizer is offering its support, in the form of for NGO and social enterprises that are working on addressing this major health challenge: antimicrobial resistance. Recipients of the one-year Global Health Innovation Grants include partners in 12 low- and middle-income countries who will each receive $100,000. → While Biogen ‘s spinal muscular atrophy treatment, Spinraza , rivals Novartis ‘ gene-therapy Zolegensma, the US drugmaker has tied up with genetics company Invitae to usher in a new genetic test for SMA, which will be offered at
More from ENDPOINTS:
GlobeNewswire 08/20/2019 07:30
Biogen discovers, develops and delivers worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases as well as related therapeutic adjacencies.
More from GlobeNewswire:
PR Newswire 08/13/2019 04:53
Data collected from 1,266 multiple sclerosis (MS) patients recently switched to a new DMT within the three months prior to fielding reveal Novartis' Gilenya, Sanofi's Aubagio, and Biogen's Tysabri and Tecfidera as the switch segment leaders in Europe.
More from PR Newswire:
FiercePharmaManufacturing 08/02/2019 10:03
Fujifilm and Biogen also struck an agreement for the CDMO to supply to Biogen the meds the Cambridge, Massachusetts-based biotech has been manufacturing at the site, including multiple sclerosis drug Tysabri.
More from FiercePharmaManufacturing:
Seeking Alpha 07/31/2019 12:13
Most recently, back on March 21, Biogen announced its potential Alzheimer's therapy aducanumab trial would be discontinued due to lack of effectiveness.
More from Seeking Alpha:
Pharmafile 07/31/2019 07:37
Biogen and Alkermes have unveiled new Phase 3 data for diroximel fumarate, comparing the adequacy of the therapy to Biogen’s own Tecfidera (dimethyl fumarate) in the treatment of patients with relapsing-remitting multiple sclerosis (RRMS.
More from Pharmafile:
STAT 07/25/2019 13:33
A pair of consumer advocacy groups wants antitrust authorities in Italy and Belgium to investigate Biogen (BIIB) for allegedly abusing its “position in the marketplace” by imposing an “unfair price” for Spinraza, a pricey therapy for treating a rare and fatal childhood disease called spinal muscular atrophy.
More from STAT:
Benzinga 07/25/2019 11:25
Pune, July 25, 2019 (GLOBE NEWSWIRE) --. Neurodegenerative Diseases Drugs Market Size, Share and Global Trends. The global neurodegenerative diseases drugs market's growth is expected to derive growth from the rising prevalence of neurodegenerative diseases especially among the aging population.
More from Benzinga:
Motley Fool 07/24/2019 15:31
Biogen (NASDAQ:BIIB) put up relatively impressive sales numbers in the second quarter, with earnings per share growing like gangbusters as the drugmaker cut expenses and repurchased shares to boost the bottom line.
More from Motley Fool:

Therapeutic Areas

Clinical Trials and Phases

Business Issues

Companies - Public

Companies - Venture Funded

Financial Results

Global Markets

Global Risk Factors

Government Agencies

Job Titles

Legal and Regulatory

Cell Receptors


Diagnostics and Therapeutics


Drugs - Brand Names

Drugs - Generic



Health Care

Health and Wellness

Human Anatomy

Mechanisms of Action

Medical Devices



Strategic Scenarios



On this page, you see the results of the search you have run.  You may also view the following:

  •  Click on this drop-down menu on the right hand side of the page, to choose between the machine learning-produced Insights Reports, or the listing of concepts extracted from the results, in chart or list format. 

  •  View the number of search results returned for the search in each of your collections, and click on any of those numbers to view the entire listing of results from the chosen collection.

  •  Use the search adjustment drop-downs to change the scope, sorting, and presentation of your results.

  •  Show or hide the record’s caption (content description).

  •  Show actions that can be made with the search result record.

  •  Click on the Save button after running your search, to save it so that its results will be updated each time relevant new content is added to the designated collection. You may choose to be notified via search alerts.

Click here for more info on Search Results

Click here for more info on Machine Learning applications